IOLCP Q2 : STANDALONE NET PROFIT UP 116.8% AT ₹65 CR (YOY)

• Revenue up 40.1% at ₹795 Cr (YoY); H1 up 38.6%. • EBITDA up 79.6% at ₹114.9 Cr (YoY); margins 14.4% v 11.1% (YoY), H1 14.5% v 11.8%. • PAT margin 8.1% v 5.2% (YoY); H1 8.3% v 5.6%. • Non-Ibuprofen portfolio revenue up ~70% (YoY), 45% of pharma revenue v 38%. • Records highest-ever quarterly revenue, EBITDA and PAT.

IOL Chemicals & Pharmaceuticals Ltd

Open attachment

← Back to feed